Pharmacogenomics for Neurodegenerative Disorders
Author Information
Author(s): Ahmad S. Rehan, Zeyaullah Md., Khan Mohammad Suhail, AlShahrani Abdullah M., Altijani Abdelrhman A. Galaleldin, Ali Haroon, Dawria Adam, Mohieldin Ali, Alam Mohammad Shane, Mohamed Awad Osman Abdalla
Primary Institution: King Khalid University
Hypothesis
Pharmacogenomics aims to tailor medical treatments based on an individual’s genetic profile to improve therapeutic efficacy and reduce adverse effects in neurodegenerative disorders.
Conclusion
Pharmacogenomics has the potential to revolutionize the treatment of neurodegenerative disorders by enabling more personalized and effective therapeutic strategies.
Supporting Evidence
- Pharmacogenomics can enhance treatment strategies and outcomes for individuals with Alzheimer's disease by customizing drugs according to genetic profiles.
- Genetic testing can guide the selection and dosage of medications for Parkinson's disease, improving therapeutic results.
- Pharmacogenomic methods can expedite the creation of precise treatments for Huntington's disease by utilizing genetic knowledge.
- Pharmacogenomics can improve the management of ALS and enhance therapy outcomes by integrating genetic findings.
Takeaway
This study talks about how understanding our genes can help doctors choose the best medicine for people with brain diseases like Alzheimer's and Parkinson's.
Methodology
This is a focused review exploring genetic factors influencing drug responses in neurodegenerative diseases and the potential of pharmacogenomics.
Potential Biases
Ethical concerns regarding genetic privacy and access to pharmacogenomic testing may lead to disparities in treatment.
Limitations
The complexity of polygenic influences and the interplay between genetic and environmental factors complicate the identification of reliable genetic markers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website